JP2024543019A - β鎖媒介免疫を調節するための組成物及び方法 - Google Patents

β鎖媒介免疫を調節するための組成物及び方法 Download PDF

Info

Publication number
JP2024543019A
JP2024543019A JP2024525726A JP2024525726A JP2024543019A JP 2024543019 A JP2024543019 A JP 2024543019A JP 2024525726 A JP2024525726 A JP 2024525726A JP 2024525726 A JP2024525726 A JP 2024525726A JP 2024543019 A JP2024543019 A JP 2024543019A
Authority
JP
Japan
Prior art keywords
antibody
cdr1
cdr2
cdr3
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024525726A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024543019A5 (enExample
Inventor
ガネサン，ラクマー
グレワル，イクバル，エス．
シン，サンジャヤ
ハンセン，マイケル，リース
Original Assignee
ヤンセン バイオテツク，インコーポレーテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヤンセン バイオテツク，インコーポレーテツド filed Critical ヤンセン バイオテツク，インコーポレーテツド
Publication of JP2024543019A publication Critical patent/JP2024543019A/ja
Publication of JP2024543019A5 publication Critical patent/JP2024543019A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024525726A 2021-11-01 2022-11-01 β鎖媒介免疫を調節するための組成物及び方法 Pending JP2024543019A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163274446P 2021-11-01 2021-11-01
US202163274449P 2021-11-01 2021-11-01
US202163274430P 2021-11-01 2021-11-01
US63/274,449 2021-11-01
US63/274,446 2021-11-01
US63/274,430 2021-11-01
PCT/US2022/079051 WO2023077155A1 (en) 2021-11-01 2022-11-01 Compositions and methods for the modulation of beta chain-mediated immunity

Publications (2)

Publication Number Publication Date
JP2024543019A true JP2024543019A (ja) 2024-11-19
JP2024543019A5 JP2024543019A5 (enExample) 2025-11-11

Family

ID=84364285

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024525726A Pending JP2024543019A (ja) 2021-11-01 2022-11-01 β鎖媒介免疫を調節するための組成物及び方法

Country Status (10)

Country Link
US (1) US20250092134A1 (enExample)
EP (2) EP4426734A1 (enExample)
JP (1) JP2024543019A (enExample)
KR (1) KR20240099397A (enExample)
CN (1) CN119390841A (enExample)
AU (1) AU2022377084A1 (enExample)
CA (1) CA3237038A1 (enExample)
IL (1) IL312464A (enExample)
MX (1) MX2024005336A (enExample)
WO (1) WO2023077155A1 (enExample)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020183245A2 (en) * 2019-03-11 2020-09-17 Janssen Pharmaceutica Nv ANTI-Vβ17/ANTI-CD123 BISPECIFIC ANTIBODIES

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
WO2006028936A2 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
KR101374454B1 (ko) 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 회합제어에 의한 폴리펩티드 제조방법
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
US9067986B2 (en) 2009-04-27 2015-06-30 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
PT2560993T (pt) 2010-04-20 2024-09-16 Genmab As Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas
CN103429620B (zh) 2010-11-05 2018-03-06 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
US9574010B2 (en) 2011-11-04 2017-02-21 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the Fc domain

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020183245A2 (en) * 2019-03-11 2020-09-17 Janssen Pharmaceutica Nv ANTI-Vβ17/ANTI-CD123 BISPECIFIC ANTIBODIES

Also Published As

Publication number Publication date
CN119390841A (zh) 2025-02-07
AU2022377084A1 (en) 2024-06-20
EP4426734A1 (en) 2024-09-11
IL312464A (en) 2024-06-01
MX2024005336A (es) 2024-07-22
EP4524160A2 (en) 2025-03-19
EP4524160A3 (en) 2025-09-24
WO2023077155A1 (en) 2023-05-04
CA3237038A1 (en) 2023-05-04
US20250092134A1 (en) 2025-03-20
KR20240099397A (ko) 2024-06-28

Similar Documents

Publication Publication Date Title
JP7686571B2 (ja) Ｔ細胞媒介性免疫を調節するための材料及び方法
US12076413B2 (en) Compositions and methods for modulating delta gamma chain mediated immunity
WO2022081516A1 (en) Bioengineered t cell mediated immunity, materials and other methods for modulating cluster of differentiation iv &/or viii
AU2019267349B2 (en) Anti-DLL3 antibodies and uses thereof
US20220127359A1 (en) Anti-vbeta17/anti-cd123 bispecific antibodies
US12448449B2 (en) Immune targeting molecules and uses thereof
US20260103521A1 (en) Methods and Compositions for Modulating Beta Chain Mediated Immunity
US20240124574A1 (en) Bispecific Antibodies with Charge Pairs and Uses Thereof
US20250092134A1 (en) Compositions and methods for the modulation of beta chain-mediated immunity
CN116615456A (zh) 用于调节β链介导的免疫的方法和组合物
CN118488966A (zh) 用于调节β链介导的免疫的组合物和方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251031

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251031

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260616